Mass spectrometry assays of plasma biomarkers to predict radiographic progression of knee osteoarthritis

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Ritter, Susan Y ^a,b   Collins, Jamie ^a   Krastins, Bryan ^c   Sarracino, David ^c   Lopez, Mary ^c   Losina, Elena ^a,b   Aliprantis, Antonios O ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Thermo Fisher Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMIN; AGGRECAN; BIOLOGICAL MARKER; CARTILAGE ACIDIC PROTEIN 1; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CLUSTERIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; DICKKOPF 1 PROTEIN; DIPEPTIDASE; FATTY ACID BINDING PROTEIN 5; FOLLISTATIN; HYALURONIC ACID; KALLISTATIN; LUBRICIN; LUMICAN; PHOSPHOLIPASE A2 GROUP XV; PIGMENT EPITHELIUM DERIVED FACTOR; PROCOLLAGEN C ENDOPEPTIDASE ENHANCER 1; PROTEIN S100 A16; PROTEOGLYCAN; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN; STROMELYSIN; UNCLASSIFIED DRUG; GLYCOPROTEIN; KERATAN SULFATE; PEPTIDE; PROTEOCHONDROITIN SULFATE; PROTEOME;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; JOINT CAVITY; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OBSERVATIONAL STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN TARGETING; RADIOLOGICAL PARAMETERS; SEX DIFFERENCE; SYNOVIAL FLUID; AGED; AMINO ACID SEQUENCE; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; PROTEOMICS; RADIOGRAPHY; STATISTICAL MODEL;

AGED; AMINO ACID SEQUENCE; BIOMARKERS; CHONDROITIN SULFATE PROTEOGLYCANS; CLUSTERIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLYCOPROTEINS; HUMANS; KERATAN SULFATE; LINEAR MODELS; MALE; MASS SPECTROMETRY; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDES; PROGNOSIS; PROTEOME; PROTEOMICS; SYNOVIAL FLUID;

EID: 84988807078     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0456-6     Document Type: Article

References (37)

1. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA: Insurer and out-of-pocket costs of osteoarthritis in the US: Evidence from national survey data. Arthritis Rheum 2009, 60:3546-3553.
2. Mobasheri A: Osteoarthritis year 2012 in review: biomarkers. Osteoarthritis Cartilage 2012, 20:1451-1464.
3. Hoofnagle AN, Wener MH: The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009, 347:3-11.
4. Agger SA, Marney LC, Hoofnagle AN: Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatographymultiple-reaction-monitoring mass spectrometry. Clin Chem 2010, 56:1804-1813.
5. Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk JE: Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin Appl 2010, 4:271-284.
6. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, HamAJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, et al: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641.
7. Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Ross MM, Zhang H, Tian Y, Kulasingam V, Crabovich AP, Smith C, Batruch I, Liotta L, Petricoin E, Diamandis EP, Chand DW, Lopez MF: Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res 2010, 9:6678-6688.
8. Ritter SY, Subbaiah R, Bebek G, Crish J, Scanzello CR, Krastins B, Sarracino D, Lopez MF, Crow MK, Aigner T, Goldring MB, Goldring SR, Lee DM, Gobezie R, Aliprantis AO: Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum 2013, 65:981-992.
9. Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, Millett PJ, Lee DM: High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007, 9:R36.
10. Mazzuca SA, Brandt KD, Katz BP, Ding Y, Lane KA, Buckwalter KA: Risk factors for progression of tibiofemoral osteoarthritis: an analysis based on fluoroscopically standardised knee radiography. Ann Rheum Dis 2006, 65:515-519.
11. Campbell J, Rezai T, Prakash A, Krastins B, Dayon L, Ward M, Robinson S, Lopez M: Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics 2011, 11:1148-1152.
12. Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Nicolaides K: Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum. J Proteome Res 2011, 10:133-142.
13. Lopez MF, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Gvozdyak O, Chou S, Lo E, Buonanno F, Ning M: Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spec-based assay for serum apolipoproteins coupled to multimarker ROC algorithm. Proteomics Clin Appl 2012, 6:190-200.
14. Neu CP, Reddi AH, Komvopoulos K, Schmid TM, Di Cesare PE: Increased friction coefficient and superficial zone protein expression in patients with advanced osteoarthritis. Arthritis Rheum 2010, 62:2680-2687.
15. Ruan MZ, Erez A, Guse K, Dawson B, Bertin T, Chen Y, Jiang MM, Yustein J, Gannon F, Lee BH: Proteoglycan 4 expression protects against the development of osteoarthritis. Sci Transl Med 2013, 5:176ra134.
16. Waller KA, Zhang LX, Elsaid KA, Fleming BC, Warman ML, Jay GD: Role of lubricin and boundary lubrication in the prevention of chondrocyte apoptosis. Proc Natl Acad Sci USA 2013, 110:5852-5857.
17. Connor JR, Kumar S, Sathe G, Mooney J, O'Brien SP, Mui P, Murdock PR, Gowen M, Lark MW: Clusterin expression in adult human normal and osteoarthritic articular cartilage. Osteoarthritis Cartilage 2001, 9:727-737.
18. Fandridis E, Apergis G, Korres DS, Nikolopoulos K, Zoubos AB, Papassideri I, Trougakos IP: Increased expression levels of apolipoprotein J/clusterin during primary osteoarthritis. In Vivo 2011, 25:745-749.
19. Devauchelle V, Essabbani A, De Pinieux G, Germain S, Tourneur L, Mistou S, Margottin-Goguet F, Anract P, Migaud H, Le Nen D, Lequerre T, Saraux A, Dougados M, Breban M, Rournier C, Chiocchia G: Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J Immunol 2006, 177:6471-6479.
20. Tschopp J, French LE: Clusterin: modulation of complement function. Clin Exp Immunol 1994, 97:11-14.
21. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH: Identification of a central role for complement in osteoarthritis. Nat Med 2011, 17:1674-1679.
22. Yamada K, Hori Y, Hanafusa N, Okuda T, Nagano N, Choi-Miura NH, Couser WG, Miyata T, Kurokawa K, Fujita T, Nangaku M: Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Int 2001, 59:137-146.
23. Jay GD, Britt DE, Cha CJ: Lubricin is a product of megakaryocyte stimulating factor gene expression by human synovial fibroblasts. J Rheumatol 2000, 27:594-600.
24. Rhee DK, Marcelino J, Baker M, Gong Y, Smits P, Lefebvre V, Jay GD, Stewart M, Wang H, Warman ML, Carpten JD: The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J Clin Invest 2005, 115:622-631.
25. Brandt KD: A pessimistic view of serologic markers for diagnosis and management of osteoarthritis. Biochemical, immunologic and clinicopathologic barriers. J Rheumatol Suppl 1989, 18:39-42.
26. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C: Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009, 17:384-389.
27. Kraus VB, Kepler TB, Stabler T, Renner J, Jordan J: First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis. PLoS One 2010, 5:e9739.
28. Golightly YM, Marshall SW, Kraus VB, Renner JB, Villaveces A, Casteel C, Jordan JM: Biomarkers of incident radiographic knee osteoarthritis: Do they vary by chronic knee symptoms? Arthritis Rheum 2011, 63:2276-2283.
29. van Lent PL, Blom AB, Schelbergen RF, Sloetjes A, Lafeber FP, Lems WF, Cats H, Vogl T, Roth J, van den Berg WB: Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum 2012, 64:1466-1476.
30. de Boer TN, van Spil WE, Huisman AM, Polak AA, Bijlsma JW, Lafeber FP, Mastbergen SC: Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. Osteoarthritis Cartilage 2012, 20:846-853.
31. Wisniewski HG, Colon E, Liublinska V, Karia RJ, Stabler TV, Attur M, Abramson SB, Band PA, Kraus VB: TSG-6 activity as a novel biomarker of progression in knee osteoarthritis. Osteoarthritis Cartilage 2014, 22:235-241.
32. Ishijima M, Watari T, Naito K, Kaneko H, Futami I, Yoshimura-Ishida K, Tomonaga A, Yamaguchi H, Yamamoto T, Nagaoka I, Kurosawa H, Poole RA, Kaneko K: Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther 2011, 13:R22.
33. van Spil WE, Jansen NW, Bijlsma JW, Reijman M, DeGroot J, Welsing PM, Lafeber FP: Clusters within a wide spectrum of biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals with very early symptomatic osteoarthritis. Osteoarthritis Cartilage 2012, 20:745-754.
34. Krastins B, Prakash A, Sarracino DA, Nedelkov D, Niederkofler EE, Kiernan UA, Nelson R, Vogelsang MS, Vadali G, Garces A, Sutton JN, Peterman S, Byram G, Darbouret B, Perusse JR, Seidah NG, Coulombe B, Gobom J, Portlius E, Panne J, Blennow K, Kulaqsingam V, Couchman L, Moniz C, Lopez MF: Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin Biochem 2013, 46:399-410.
35. Hoofnagle AN, Becker JO, Oda MN, Cavigiolio G, Mayer P, Vaisar T: Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin Chem 2012, 58:777-781.
36. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, Eng J, Chen S, Eddes J, Loevenich SN, Aebersold R: The PeptideAtlas project. Nucleic Acids Res 2006, 34:D655-D658.
37. Bystrom C, Sheng S, Zhang K, Caulfield M, Clarke NJ, Reitz R: Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS One 2012, 7:e43457.